Los Angeles Capital Management LLC Has $1.19 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Los Angeles Capital Management LLC lowered its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 5.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 9,585 shares of the company’s stock after selling 538 shares during the period. Los Angeles Capital Management LLC’s holdings in Krystal Biotech were worth $1,189,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KRYS. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 40.7% during the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock valued at $278,416,000 after buying an additional 693,852 shares during the last quarter. Jennison Associates LLC lifted its stake in Krystal Biotech by 112.5% during the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock valued at $89,862,000 after acquiring an additional 383,495 shares in the last quarter. Fred Alger Management LLC grew its stake in shares of Krystal Biotech by 4,608.6% in the 3rd quarter. Fred Alger Management LLC now owns 167,485 shares of the company’s stock worth $19,428,000 after acquiring an additional 163,928 shares in the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Krystal Biotech in the third quarter valued at about $14,272,000. Finally, Schonfeld Strategic Advisors LLC lifted its position in shares of Krystal Biotech by 356.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 83,635 shares of the company’s stock valued at $9,702,000 after purchasing an additional 65,325 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 8,087 shares of Krystal Biotech stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the transaction, the chief accounting officer now directly owns 12,556 shares of the company’s stock, valued at approximately $1,719,041.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,087 shares of company stock valued at $6,210,591. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $157.68 on Thursday. The stock has a fifty day moving average of $168.76 and a 200-day moving average of $134.27. Krystal Biotech, Inc. has a fifty-two week low of $86.03 and a fifty-two week high of $189.97. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. During the same period in the previous year, the company earned ($1.76) EPS. The firm’s revenue for the quarter was up 452400.0% on a year-over-year basis. Equities analysts predict that Krystal Biotech, Inc. will post 1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Guggenheim increased their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a report on Monday. Stifel Nicolaus reissued a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup raised their target price on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $171.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).